Collectively, the results suggest that the NEK2 inhibitor enhanced the efficacy of PD-L1 blockade both in vitro and in vivo, alleviating immuno-resistance in pancreatic cancer. The gene discussed is NEK2; the disease is familial pancreatic carcinoma.